Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4

Pharmaceutical Research

Volumn 17, Issue 4, 2000, Pages 419-426

  Kanamitsu, Shin Ichi ^a   Ito, Kiyomi ^b   Green, Carol E ^c   Tyson, Charles A ^c   Shimada, Noriaki ^d   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c SRI INTERNATIONAL   (United States)

^d DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

Drug interaction; Erythromycin; Mechanism based inhibition; Physiologically based pharmacokinetics; Triazolam

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; TRIAZOLAM;

AREA UNDER THE CURVE; ARTICLE; DRUG INHIBITION; DRUG METABOLISM; ENZYME INACTIVATION; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KINETICS; LIVER MICROSOME; METABOLIC INHIBITION; MODEL; PRIORITY JOURNAL; QUANTITATIVE ASSAY;

AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RECOMBINANT PROTEINS; TRIAZOLAM;

EID: 0034089555     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007572803027     Document Type: Article

References (25)

1. 1. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare: A report on investigation of side effects of sorivudine: deaths caused by interaction between sorivudine and 5-FU pro-drugs (in Japanese). June, 1994.
2. 2. H. Okuda, T. Nishiyama, K. Ogura, S. Nagayama, K. Ikeda, S. Yamaguchi, Y. Nakamura, Y. Kawaguchi, and T. Watabe. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos. 25:270-273 (1997).
3. 3. C. Desgranges, G. Razaka, E. D. Clercq, P. Herdewijn, J. Balzarini, F. Drouillet, and H. Bricaud. Effect of (E)-5-(2-Bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 46:1094-1101 (1986).
4. 4. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama. Prediction of pharmacokinetic alterations caused by drug-drug interactions. Pharmacol. Rev. 50:387-411 (1998).
5. 5. P. Periti, T. Mazzei, E. Mini, and A. Novelli. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:106-131 (1992).
6. 6. J. P. Phillips, E. J. Antal, and R. B. Smith. A pharmacokinetic drug interaction between erythromycin and triazolam. J. Clin. Psychopharmacol. 6:297-299 (1986).
7. 7. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4:879-885 (1981).
8. 8. S. G. Waley. Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem. J. 227:843-849 (1985).
9. 9. R. B. Silverman. Mechanism-based enzyme inactivation. In Chemistry and Enzymology, Vols. 1 and 2, CRC Press, Boca Raton, FL, 1988, pp. 3-16.
10. 10. F. S. Jr. Eberts, Y. Philopoulos, L. M. Reineke, and R. W. Vliek. Triazolam disposition. Clin. Pharmacol. Ther. 29:81-93 (1981).
11. 11. MARTINDALE the Extra Pharamcopoeia, Thirty-first edition, the Royal Pharmaceutical Society of Great Britain, London, 1996.
12. 12. H. Shiraki and F. P. Guengerich. Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydrolase. Arch. Biochem. Biophys. 235:86-96 (1984).
13. 13. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, and Y. Sugiyama. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73:147-171 (1997).
14. 14. Goodman and Gilman's The pharmacological basis of therapeutics, Ninth edition, J. G. Hardman and L. E. Limbird (eds.), MacGraw-Hill, New York, 1996.
15. 15. D. J. Birkett, R. A. Robson, N. Grgurinovich and A. Tonkin. Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther. Drug Monit. 12: 65-71 (1990).
16. 16. T. Kronbach, D. Mathys, M. Umeno, F. J. Gonzalez, and U. A. Meyer. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36:89-96 (1989).
17. 17. L. L. von Moltke, D. J. Greenblatt, J. S. Harmatz, S. X. Duan, L. M. Harrel, M. M. Cotreau-Bibbo, G. A. Pritchard, C. E. Wright, and R. I. Shader. Triazolam biotransformation by human liver microsomes in vitro: Effect of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276:370-379 (1996).
18. 18. S. A. Wrighton and B. J. Ring. Inhibition of human CYP3A catalyzed l'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 11:921-924 (1994).
19. 19. K. E. Thummel and G. R. Wilkinson. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38:389-460 (1998).
20. 20. H. Echizen, H. Kawasaki, K. Chiba, M. Tani, and T. Ishizaki. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J. Pharmacol. Exp. Ther. 264:1425-1431 (1993).
21. 21. M. Murray. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metab. Rev. 18:55-81 (1987).
22. 22. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38:461-499 (1998).
23. 23. S. Kanamitsu, K. Ito, H. Okuda, K. Ogura, T. Watabe, K. Muro, and Y. Sugiyama. Prediction of in vitro drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl) uracil. Drug Metab. Dispos. (in press).
24. 24. J. C. Kolars, W. M. Awni, R. M. Merion, and P. B. Watkins. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490 (1991).
25. 25. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Phamracol. Ther. 59:491-502 (1996).